Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 41.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,900 shares of the biopharmaceutical company's stock after selling 4,100 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Alnylam Pharmaceuticals were worth $1,623,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ALNY. Cetera Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $238,000. GAMMA Investing LLC increased its stake in Alnylam Pharmaceuticals by 97.2% in the second quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 205 shares during the last quarter. CWM LLC raised its position in Alnylam Pharmaceuticals by 102.8% during the second quarter. CWM LLC now owns 3,492 shares of the biopharmaceutical company's stock valued at $849,000 after purchasing an additional 1,770 shares in the last quarter. Symmetry Partners LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $278,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 13.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,308 shares of the biopharmaceutical company's stock worth $804,000 after purchasing an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares of the company's stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,370 shares of company stock worth $2,100,703 over the last 90 days. Company insiders own 1.50% of the company's stock.

Analyst Ratings Changes

ALNY has been the subject of a number of recent research reports. Chardan Capital restated a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Royal Bank of Canada restated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $298.09.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $4.45 on Friday, reaching $256.26. The company's stock had a trading volume of 574,959 shares, compared to its average volume of 867,049. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market capitalization of $33.05 billion, a price-to-earnings ratio of -96.11 and a beta of 0.32. The stock's fifty day simple moving average is $269.49 and its 200-day simple moving average is $243.89. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same period last year, the business posted $1.15 EPS. The business's revenue for the quarter was down 33.3% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.